Ohio State-originated drug to treat castration-resistant prostate cancer licensed to startup

Story excerpt provided by Columbus Business First.

Written by Carrie Ghose.

A pharmaceutical startup has licensed from Ohio State University and research partners a pill for treating prostate cancer at the stage when the tumor resists extreme testosterone suppression therapy and is spreading.

Click here to read the complete article.

Originally published October 1, 2015.